Reduced lung-cancer mortality with low-dose computed tomographic screening.

Area of Science:

• Oncology
• Radiology
• Public Health

Background:

• Lung cancer's aggressive nature has historically limited mortality reduction through screening.
• Low-dose helical computed tomography (CT) has emerged as a promising tool for early-stage lung cancer detection.
• The National Lung Screening Trial (NLST) aimed to evaluate the efficacy of low-dose CT screening in reducing lung cancer mortality.

Purpose of the Study:

• To determine if low-dose CT screening reduces lung cancer mortality.
• To compare the effectiveness of low-dose CT versus chest radiography in lung cancer screening.
• To assess the incidence of lung cancer and mortality rates in high-risk individuals undergoing screening.

Main Methods:

• Enrolled 53,454 high-risk individuals across 33 U.S. medical centers from August 2002 to April 2004.
• Randomly assigned participants to three annual screenings: low-dose CT (26,722) or single-view posteroanterior chest radiography (26,732).
• Collected data on lung cancer cases and deaths through December 31, 2009.

Main Results:

• Low-dose CT screening demonstrated a 20.0% relative reduction in lung cancer mortality (95% CI, 6.8 to 26.7; P=0.004).
• Overall mortality from any cause was also reduced by 6.7% in the low-dose CT group (95% CI, 1.2 to 13.6; P=0.02).
• While low-dose CT had a higher positive screening rate (24.2%), the majority of these were false positives (96.4%).

Conclusions:

• Screening high-risk individuals with low-dose CT significantly reduces lung cancer mortality.
• Low-dose CT screening is an effective strategy for early detection and improved survival in lung cancer.
• The NLST provides robust evidence supporting the use of low-dose CT for lung cancer screening programs.